Jennifer Kristin Lenchik, WHNP-BC
Nurse Practitioner · Clemmons
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Hospitals listed: North Carolina Baptist Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Jennifer Kristin Lenchik’s office at (336) 716-4039 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- North Carolina Baptist HospitalWinston-Salem, NCAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Advocate Health, which runs 58 hospitals in 6 statesHome of Wake Forest Baptist Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.45 (0.98 to 1.91) · 9,389 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.242, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.353, Oct 2024 – Sep 2025Better than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 8.6 (7.1 to 10.6) · 706 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for North Carolina Baptist Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.45 (0.98 to 1.91) · 9,389 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.353 | Better | Oct 2024 – Sep 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.6 (7.1 to 10.6) · 706 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.2 to 1.74) · 2,706 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.87 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 156.03 (119.34 to 192.72) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.6 · 239 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.9 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.3 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 297 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 631 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 7,258 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.29) · 10,835 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.33 (0.15 to 0.51) · 11,325 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.16 (1.65 to 4.67) · 4,146 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.09 (0 to 2.19) · 1,971 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.02 to 3.11) · 3,871 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.83 (3.98 to 11.68) · 1,896 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.48 (1.04 to 5.92) · 2,029 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.45 to 3.03) · 1,078 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.7 · 38 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.754 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.126 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.035 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.314 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14 · 713 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.3 · 1,362 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.5 · 377 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.9 · 613 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26 · 317 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 774 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (4.3 to 7) · 706 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 39 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 288 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.6 to 16.4) · 981 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.1) · 1,205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,479 patients answered, 20% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$1,321
Medicare paid this office $1,321 for 29 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 21 | $919 | $37 |
Who their Medicare patients are
29 Original Medicare patients in 2024. Average age 64 · Women 100% · Health risk score 0.95. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 48%.
The office billed $5,300, Medicare allowed $1,833 and paid $1,321; for 39 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 29 | 39 | 64 | 0.95 | $5,300 | $1,321 |
| 2023 | 25 | 34 | 67 | 0.80 | $4,174 | $1,001 |
| 2021 | 14 | 51 | 40 | 0.72 | $8,758 | $1,608 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 16 | $352 | $22 |
Medicaid work
$6,457 in 2024
Medicaid paid $6,457 for 341 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 148 | $5,648 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 15 | $405 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 15 | $405 |
| Postoperative follow-up visit, normally included in the surgical package, to indicate that an evaluation and management service was performed during a postoperative period for a reason(s) related to the original procedure | 163 | $0 |
| 2024 | 341 | 4 | 27 | $6,457 |
| 2023 | 415 | 2 | 25 | $14,908 |
| 2022 | 2,231 | 22 | 38 | $49,695 |
| 2021 | 3,195 | 19 | 32 | $57,699 |
| 2020 | 1,173 | 19 | 27 | $18,680 |
| 2019 | 1,322 | 13 | 24 | $13,855 |
| 2018 | 139 | 2 | 19 | $270 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 401 | $14,756 |
| URINE BACTERIA CULTURE | 14 | $152 |
2022
| Short return visit (20+ min) | 312 | $14,335 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 153 | $5,337 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 122 | $4,647 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 122 | $4,527 |
| Medical home program, comprehensive care coordination and planning, initial plan | 80 | $3,518 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 102 | $2,908 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 38 | $2,724 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 21 | $2,454 |
| URINE BACTERIA CULTURE | 215 | $2,429 |
| URINE PREGNANCY TEST | 258 | $1,735 |
| Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) | 150 | $938 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 339 | $850 |
2021
| Short return visit (20+ min) | 270 | $13,636 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 263 | $7,117 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 232 | $7,093 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 232 | $7,026 |
| Medical home program, comprehensive care coordination and planning, initial plan | 71 | $3,408 |
| URINE BACTERIA CULTURE | 310 | $2,964 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 16 | $2,529 |
| URINE PREGNANCY TEST | 309 | $2,230 |
| ANTIBODY SCREEN RBC EACH SERUM TECHNIQUE | 100 | $1,919 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 204 | $1,807 |
| Antibody; rubella | 97 | $1,551 |
| IAAD IA HEPATITIS B SURFACE ANTIGEN | 136 | $1,253 |
2020
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 136 | $3,911 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 73 | $2,142 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 73 | $2,142 |
| Medical home program, comprehensive care coordination and planning, initial plan | 42 | $2,053 |
| URINE BACTERIA CULTURE | 171 | $1,665 |
| Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; single or first gestation | 12 | $1,155 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 133 | $1,037 |
| URINE PREGNANCY TEST | 144 | $967 |
| Short return visit (20+ min) | 18 | $756 |
| Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) | 137 | $701 |
| ANTIBODY SCREEN RBC EACH SERUM TECHNIQUE | 28 | $648 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 40 | $547 |
2019
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 108 | $2,844 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 108 | $2,842 |
| Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result | 110 | $2,757 |
| URINE PREGNANCY TEST | 220 | $1,382 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 208 | $1,214 |
| URINE BACTERIA CULTURE | 107 | $1,008 |
| ANTIBODY SCREEN RBC EACH SERUM TECHNIQUE | 28 | $687 |
| Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) | 110 | $493 |
| Blood typing for Rh (D) antigen | 29 | $218 |
| Blood group typing (ABO) | 29 | $194 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 221 | $132 |
| GLUCOSE POST GLUCOSE DOSE | 25 | $82 |
2018
| URINE BACTERIA CULTURE | 54 | $222 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 85 | $48 |
Drugs they prescribed that Part D paid
$13,484
Pharmacies billed $13,484 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 141) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
128 generic and 13 brand-name prescriptions · $13,484 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 48 | $2,190 | $46 |
| Valacyclovir | 14 | $629 | $45 |
| Norethindrone | 11 | $122 | $11 |
Year by year
| 2024 | 141 | 44 | 0% (0) | 9% | $13,484 |
| 2023 | 67 | 32 | 0% (0) | None | $4,943 |
| 2022 | 36 | 16 | 0% (0) | None | $2,322 |
| 2021 | 41 | 13 | 0% (0) | None | $2,594 |
| 2020 | 27 | 12 | 0% (0) | 0% | $1,115 |
| 2019 | 33 | 12 | 0% (0) | None | $2,437 |
| 2018 | 14 | None | 0% (0) | None | $818 |
| 2017 | 15 | 12 | 0% (0) | None | $1,372 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Estradiol | 23 | $1,202 | $52 |
Professional record
- NPI
- 1992221709
- Licence
- NC 261539, NC 5009702
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 163WW0101X (163WW0101X); Federal specialty code 363LW0102X (363LW0102X)
- Mailing address
- 421 Fayetteville St Ste 1100, Raleigh, NC, 27601
- NPI first listed
- 2017-08-15
- NPI last updated
- 2025-06-23
- NPI record certified
- 2025-06-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 136 S Park St, Asheboro, NC, 27203 · 195 Page Mill Rd Ste 103, Palo Alto, CA, 94306 · 421 Fayetteville St Ste 1100, Raleigh, NC, 27601 · 114 Charlois Blvd, Winston Salem, NC, 27103
This office lists an electronic records connection.